Evidence review · from the 250-topic plan
The titration schedule, annotated: every rung of the ladder — and what each one costs
Tirzepatide's label ladder runs 2.5 mg (a four-week introduction) → 5 → 7.5 → 10 → 12.5 → 15 mg, stepping every four weeks as tolerated, with 5, 10, and 15 all recognized maintenance doses; semaglutide's runs 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg on the same cadence. Two annotations most pages skip: holding or stepping back a rung is standard practice, not failure — and in dose-tiered programs, every rung upward is also a billing event. This piece walks the ladder clinically, then prices it, because the market has made your dose schedule a financial document.
Why ladders exist at all
Side effects cluster at dose changes; efficacy lives at steady state. Four-week rungs let the gut adapt while blood levels plateau (both molecules carry multi-day half-lives, so each rung takes weeks to fully arrive). Climb faster and you buy nausea without speed — the pivotal trials' results were produced by this pacing. Any program hurrying you up the ladder is optimizing something other than your comfort; in tiered-pricing programs, it isn't hard to guess what.
Tirzepatide, rung by rung
2.5 mg, weeks 1–4: labeled for treatment initiation, not maintenance — the handshake dose. Appetite often quiets here anyway. 5 mg: the first maintenance-eligible rung and, per SURMOUNT-1, a ~15%-average therapy on its own — the most underrated number in the file. 7.5 and 10 mg: the middle band where a large share of real-world patients settle, adding effect as tolerated; 10 mg averaged ~19.5% in the trial. 12.5 and 15 mg: the top band — home of 20.9%, and of the most escalation-week GI attention. The label's own architecture says it plainly: maintenance is 5, 10, or 15 — the lowest rung that keeps working for you, not the biggest number printed.
Semaglutide's mirror
0.25 mg: pure introduction, sub-therapeutic by design. 0.5 → 1.0 → 1.7: the climb, four weeks each, effect building through the middle. 2.4 mg: the studied weight-management maintenance dose behind STEP 1's ~14.9%. Same grammar throughout: patients who plateau tolerably at a middle rung often hold there, and results below the ceiling are still results.
"As tolerated," decoded
The label's three most load-bearing words license real flexibility: holding a rung an extra two-to-eight weeks, stepping back one after a rough escalation, pacing around surgeries and life events. What they don't license: skipping rungs upward, doubling missed doses, or DIY schedule surgery between visits. The tell of a real medical program is that titration is managed one-on-one — holds included — rather than dispensed on a conveyor.
The pricing annotation the label doesn't carry
Here is the market's quiet trick: in dose-tiered programs, the clinical ladder above doubles as a price list. On-record examples in our field run entry rates near $199 tiering toward $299 at maintenance — so the climb from 2.5 to a 10-or-15 mg maintenance dose carries roughly $80–$100/month of added bill, ~$1,000 across year one, versus flat pricing. That's the step-up tax, and it does something worse than cost money: it puts a thumb on a medical decision, because "should we try 10 mg?" now has a billing answer. The audited counter-model is dose-proof flat pricing — $139/month at every rung, $1,668 for the year — where the only variable in a dose conversation is the medicine. Run any program's ladder through the calculator before believing its door price. The dose-proof benchmark ↗
The four questions to ask any program
In writing, before paying: What will my price be at 10 mg and at 15 mg (or at 2.4 mg)? Does holding a dose or stepping back change my bill or my plan? Who decides my titration pace — a clinician I can message, or a refill algorithm? What happens to price and protocol if I switch molecules mid-plan? Programs with good answers volunteer them; programs with bad ones have a chat widget.
FAQ
What is the standard tirzepatide titration schedule?
2.5 mg weekly for four weeks, then steps of 2.5 mg every four weeks as tolerated toward 5, 10, or 15 mg maintenance — all three are label-recognized maintenance doses.
Is it bad to stay at a lower dose?
No — 5 mg averaged ~15% in SURMOUNT-1 and 10 mg ~19.5%; the right maintenance dose is the lowest that keeps working, decided with a clinician.
Why do some programs charge more at higher doses?
Dose-tiered pricing bills the ladder — commonly $80–$100/month more by maintenance (~$1,000/year). Flat, dose-proof pricing removes both the cost and the conflict of interest.
Can titration be slowed down?
Yes — holding rungs or stepping back is standard "as tolerated" practice; what's off-limits is skipping upward or doubling missed doses.
Sources
- Zepbound and Wegovy prescribing information — titration schedules and maintenance-dose language.
- SURMOUNT-1 dose-response results (NEJM 2022); STEP 1 (NEJM 2021).
- On-record tiered pricing and audited flat pricing — the open dataset, 2026-08-14.